Dec 2025 (Q4 FY25) — Jan 29, 2026
Sanofi Q4 FY25 — Strong Sales Growth and Pipeline Delivery
Read the full callSanofi (SNY) earnings
- Dec 2025 (Q4 FY25)
- Dec 2025
Sanofi earnings: last reported Thu, 29 Jan 2026, for the quarter ended Dec 2025.
Price
$39.57 −2.56% · −$1.04
Performance −21.8% 1Y
1Y: $50.62 on 17 Oct 2025 → $39.57. High $52.34 (13 Nov 2025), low $39.12 (13 Oct 2026).
- Previous close
- $40.61
- 52-week range
- $39.12 – $52.34
- One year
- −20.43%
Overview
- Symbol
- SNY
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Sanofi earnings calls (SNY)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Fixed assets | 11,050 | 10,916 | 11,492 | 11,358 | 10,526 | 11,227 | 10,484 | 11,811 |
| Total assets | 127,562 | 126,529 | 140,396 | 136,186 | 135,162 | 139,743 | 137,964 | 148,996 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6,351 | 8,667 | 9,103 | 11,917 | 11,227 | 11,335 | 9,434 | 12,631 |
| Cash from investing | -14,732 | -1,329 | 4,441 | -8,266 | -2,213 | -6,851 | -4,578 | -2,875 |
| Cash from financing | 4,504 | -4,710 | -7,958 | -7,992 | -6,209 | -8,897 | -5,987 | -9,643 |
| Net cash flow | -3,882 | 2,811 | 5,507 | -4,323 | 2,814 | -4,449 | -1,318 | 254 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of SNY filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Sanofi
Free account. Everything above stays public.
Write why you follow Sanofi and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading